{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:07:18Z","timestamp":1787170038510,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Many coronavirus disease 2019 (COVID-19) vaccines were approved worldwide. Their safety was the primary concern. In Egypt, Oxford\u2013AstraZeneca (AZ) vaccine was the first approved vaccine initially for healthcare workers (HCWs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We aim to determine adverse events and hematological abnormalities following the COVID-19 AZ vaccine and estimate the infection rate of the candidates by COVID-19 between the first and second doses of vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Within 8\u201310 days of receiving their initial dose of the AZ vaccine, 909 HCWs were assessed for adverse events as part of a prospective longitudinal study. Complete blood counts (CBCs) were evaluated before and one month after vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>37.2% of the candidates experienced side effects following vaccination. Pain at the injection site was the most common (25.4%) and more frequent in participants between 20 and 40 years (27.9%). The mean total leukocyte count (TLC), absolute leukocyte count (ALC), absolute neutrophil count (ANC), and absolute monocyte count (AMC) increased one month following vaccination (P &lt; 0. 001). Sixty-six vaccinated HCWs were infected with COVID-19 between the two vaccine doses. 82% were infected after 14 days of the first dose, while 18% were infected before 14 days (P &lt; 0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Most of the vaccinated personnel did not experience any side effects after the first dose of the vaccine. Furthermore, the most common complaints were pain at the injection site, fatigue, fever, headache, arthralgia, myalgia, and chills. Infected people with COVID-19 after the first dose had significantly more severe disease if they were infected before 14 days than those who got infected later on.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijoem.ijoem_275_22","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T08:37:44Z","timestamp":1696581464000},"page":"241-248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Impact of SARS-CoV-2 AstraZeneca Vaccine on Safety and Blood Elements of Egyptian Healthcare Workers"],"prefix":"10.4103","volume":"27","author":[{"given":"Taghreed S.","family":"Meshref","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Critical Care Unit, Faculty of Medicine, Assiut University, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina A.","family":"Hamad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Critical Care Unit, Faculty of Medicine, Assiut University, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai M.","family":"Aly","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Clinical Hematology Unit, Faculty of Medicine, Assiut University, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia T.","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam R.","family":"Elkhayat","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Medicine, Assiut University, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa A.","family":"Elghazally","sequence":"additional","affiliation":[{"name":"Department of Public Health, Faculty of Medicine, Assiut University, Assiut, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"R2-20240902","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"R3-20240902","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/vaccines10010109","article-title":"Side effects and efficacy of COVID-19 vaccines among the egyptian population","volume":"10","author":"Elgendy","year":"2022","journal-title":"Vaccines"},{"key":"R4-20240902","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.4161\/hv.28559","article-title":"Systemic inflammatory reaction after pneumococcal vaccine: a case series","volume":"10","author":"von Elten","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R5-20240902","doi-asserted-by":"crossref","first-page":"e0157385","DOI":"10.1371\/journal.pone.0157385","article-title":"Neutropenia as an adverse event following vaccination: Results from randomized clinical trials in healthy adults and systematic review","volume":"11","author":"Muturi-Kioi","year":"2016","journal-title":"PLoS One"},{"key":"R6-20240902","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"key":"R7-20240902","first-page":"Cd015477","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Gra\u00f1a","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-20240902","first-page":"860","article-title":"Adverse effects of Oxford-AstraZeneca COVID-19 vaccine among Egyptian healthcare workers","volume":"3","author":"Al Kaffas","year":"2022","journal-title":"Microbes and Infectious Diseases"},{"key":"R9-20240902","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"R10-20240902","first-page":"9","article-title":"Clinical management of severe acute respiratory infection (SARI) when COVID\u201019 disease is suspected. Interim guidance","volume":"16","year":"2020","journal-title":"Paediatr Fam Med"},{"key":"R11-20240902","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.18632\/aging.103170","article-title":"Typical radiological progression and clinical features of patients with coronavirus disease 2019","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"R12-20240902","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(17)30131-9","article-title":"CEPI\u2014a new global R&D organisation for epidemic preparedness and response","volume":"389","author":"Brende","year":"2017","journal-title":"Lancet"},{"key":"R13-20240902","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40264-020-01002-6","article-title":"Assessing the safety of COVID-19 vaccines: A primer","volume":"43","author":"Petousis-Harris","year":"2020","journal-title":"Drug Saf"},{"key":"R14-20240902","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/vaccines9060674","article-title":"Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia","volume":"9","author":"Alhazmi","year":"2021","journal-title":"Vaccines"},{"key":"R15-20240902","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdO\u00d71 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20240902","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.2147\/IDR.S332354","article-title":"Adverse effects of the COVID-19 vaccine reported by lecturers and staff of Kabul University of Medical Sciences, Kabul, Afghanistan","volume":"14","author":"Azimi","year":"2021","journal-title":"Infect Drug Resist"},{"key":"R17-20240902","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"R18-20240902","article-title":"Keeping up with vaccinations. What\u2019s new, what\u2019s available and who to ask for help","author":"Wood","year":"2019","journal-title":"MedicineToday"},{"key":"R19-20240902","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jamadermatol.2021.2114","article-title":"Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines","volume":"157","author":"Robinson","year":"2021","journal-title":"JAMA Dermatol"},{"key":"R20-20240902","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/0470853093.ch25","article-title":"CIOMS Working groups and their contribution to pharmacovigilance","author":"Roden","year":"2002","journal-title":"Pharmacovigilance"},{"key":"R21-20240902","article-title":"Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID\u201019 vaccination: A prospective cohort study in healthcare workers","author":"Rerknimitr","journal-title":"J Eur Acad Dermatol"},{"key":"R22-20240902","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccination","volume":"138","author":"Tiede","year":"2021","journal-title":"Blood"},{"key":"R23-20240902","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.vaccine.2008.02.071","article-title":"Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa","volume":"26","author":"Jaoko","year":"2008","journal-title":"Vaccine"},{"key":"R24-20240902","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"key":"R25-20240902","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: A national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"}],"container-title":["Indian Journal of Occupational and Environmental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijoem.ijoem_275_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:17:21Z","timestamp":1787167041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijoem.ijoem_275_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijoem.ijoem_275_22","relation":{},"ISSN":["0973-2284","1998-3670"],"issn-type":[{"value":"0973-2284","type":"print"},{"value":"1998-3670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-10-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}